A new study has shown the potential benefits the antiepileptic drug (AED) rufinamide can provide in the treatment of drug-resistant epilepsy.The research from China’s Zhejiang Chinese Medical University reviewed data from five existing randomised controlled trials, to assess the clinical efficacy and safety of the drug. Information from a total of 1,512 people was analysed.Results published in the medical journal Epilepsy Research indicated that the AED was associated with a better response rate than placebo, and that its effectiveness was possibly dose-dependent and linked to seizure type.It was also found, however, that rufinamide increased the rate of adverse events such as headaches, dizziness, fatigue, nausea and vomiting, although none of these side effects were considered serious.The researchers concluded: “This study confirmed significant effects of rufinamide as adjunctive treatment for drug-resistant seizures, both partial and tonic-atonic. However, rufinamide may induce more tolerable (but not severe) adverse events.”Rufinamide is approved as an add-on therapy for Lennox-Gastaut syndrome and is sold under the brand name Inovelon.Posted by Bob JonesEdited by Epilepsy Research UKClick here for more articles about anti-epileptic drugs and pregnancy risks.